Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Physical interfaces refer to the contact surfaces between biological molecules, most notably protein-protein interaction (PPI) sites, which are essential for the formation of functional complexes and the execution of cellular signaling pathways (Jones & Thornton, 1996, PNAS). These interfaces are characterized by specific physicochemical properties, such as hydrophobicity and shape complementarity, that allow for selective molecular recognition (Arkin et al., 2014, Chemistry & Biology). While historically considered undruggable due to their large, flat surfaces, physical interfaces have become significant therapeutic targets in oncology, immunology, and infectious diseases (Scott et al., 2016, Nature Reviews Drug Discovery). Drugs like Venetoclax demonstrate the clinical success of disrupting these interfaces to induce apoptosis in cancer cells by targeting the BCL-2/Bax interaction (Souers et al., 2013, Nature Medicine). However, Physical interfaces is a broad conceptual category rather than a specific, discrete molecular target, making it an incorrect designation for a single therapeutic entity.
Inhibition of protein-protein interaction
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Physical interfaces.